Page last updated: 2024-12-06
1-adamantanecarboxamide
## 1-Adamantanecarboxamide: A Promising Molecule for Research
1-Adamantanecarboxamide, also known as **amantadine**, is a drug that has been used for decades to treat Parkinson's disease and influenza A. However, its research significance extends beyond these therapeutic applications, highlighting its potential in various fields.
**Here's a breakdown of its importance:**
**1. Therapeutic Potential:**
* **Parkinson's Disease:** Amantadine was one of the first medications approved for Parkinson's disease. It works by increasing dopamine levels in the brain, alleviating symptoms like tremors and rigidity.
* **Influenza A:** Amantadine has antiviral activity against influenza A virus, particularly effective in treating the initial stages of infection. However, its effectiveness has declined with the emergence of resistant strains.
**2. Research Applications:**
* **Neuroprotection:** Studies suggest that amantadine may protect neurons from damage, potentially benefiting conditions like stroke and Alzheimer's disease.
* **Anti-inflammatory:** It has shown potential in reducing inflammation, particularly in conditions like rheumatoid arthritis and multiple sclerosis.
* **Cognitive Enhancement:** Some research suggests that amantadine might improve cognitive function, potentially helping with memory and attention.
* **Cancer Therapy:** Amantadine is being investigated for its potential in cancer treatment, particularly in inhibiting tumor growth and angiogenesis (formation of new blood vessels that feed tumors).
**3. Unique Properties:**
* **Adamantane Scaffold:** Amantadine's structure incorporates the rigid adamantane cage, providing unique properties like high stability and potential for drug delivery.
* **Versatile Chemistry:** The carboxamide group allows for modification and conjugation with other molecules, expanding its potential applications.
**4. Ongoing Research:**
* **New Formulations and Delivery Systems:** Researchers are developing new formulations and delivery methods to enhance amantadine's effectiveness and reduce side effects.
* **Mechanism of Action:** Further research is needed to understand the exact mechanisms by which amantadine exerts its therapeutic effects, which could lead to more targeted drug development.
* **New Therapeutic Applications:** Ongoing research is exploring amantadine's potential in treating a wide range of conditions, including drug addiction, neurodegenerative disorders, and autoimmune diseases.
**In conclusion, 1-adamantanecarboxamide, despite being known for its clinical applications, holds significant promise in research. Its unique properties, potential for various therapeutic applications, and ongoing research make it a molecule worth watching in the future of drug development.**
Cross-References
ID Source | ID |
PubMed CID | 21686 |
CHEMBL ID | 2041315 |
SCHEMBL ID | 176523 |
MeSH ID | M0269110 |
Synonyms (41)
Synonym |
HMS1786F09 |
brn 2047887 |
tricyclo(3.3.1.1(sup 3,7))decane-1-carboxamide |
tricyclo[3.3.1.1~3,7~]decane-1-carboxamide |
STL290663 |
1-adamantanecarboxamide |
tricyclo(3.3.1.13,7)decane-1-carboxamide |
EU-0066815 |
OPREA1_331138 |
1-adamantanecarboxamide, 97% |
5511-18-2 |
adamantane-1-carboxamide |
perazine-d8 dihydrochloride salt |
9-minocycline-d6 disulfate salt |
AKOS001023937 |
adamantanecarboxamide |
A830495 |
adamantane-1-carboxylic acid amide |
CHEMBL2041315 |
GEO-02752 |
FT-0621897 |
AKOS017344467 |
SCHEMBL176523 |
admantane-1-carboxamide |
CKBZJTAMRPPVSR-UHFFFAOYSA-N |
2,4-dinitrophenyltaurinesodiumsalt |
W-200426 |
DTXSID30203628 |
sr-01000389674 |
SR-01000389674-1 |
mfcd00077200 |
AS-58216 |
1246815-57-5 |
Z56757306 |
1-adamantyl-carboxamide |
BB 0266540 |
1316291-16-3 |
CS-0149960 |
1-adamantane carboxamide |
SY031536 |
EN300-1718711 |
Bioassays (5)
Assay ID | Title | Year | Journal | Article |
AID668903 | Inhibition of Influenza A Virus M2 proton channel expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay | 2011 | ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
| Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. |
AID668905 | Inhibition of Influenza A Virus M2 proton channel V27A mutant expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay | 2011 | ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
| Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. |
AID668906 | Inhibition of Influenza A Virus M2 proton channel S31N mutant expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay | 2011 | ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
| Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.87 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.66 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |